Collaborative Arrangements and Licensing Agreements (Tables)

12 Months Ended

Dec. 31, 2020

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2020, 2019 and 2018, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Year Ended December 31,
	2020			2019			2018
SPINRAZA royalties (commercial revenue)	$	286.6		$	293.0		$	237.9
R&D revenue		122.0			180.6			137.1
Total revenue from our relationship with Biogen	$	408.6		$	473.6		$	375.0
Percentage of total revenue		56	%		42	%		63	%

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2020, 2019 and 2018, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):

	Year Ended December 31,
	2020			2019			2018
R&D revenue	$	88.0		$	28.1		$	120.7
Percentage of total revenue		12	%		3	%		20	%

Bayer [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2020, 2019 and 2018, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):

	Year Ended December 31,
	2020			2019			2018
R&D revenue	$	3.2		$	14.3		$	5.0
Percentage of total revenue		0	%		1	%		1	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2020, 2019 and 2018, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):

	Year Ended December 31,
	2020			2019			2018
R&D revenue	$	0.2		$	25.4		$	1.6
Percentage of total revenue		0	%		2	%		0	%

Janssen Biotech, Inc. [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2020, 2019 and 2018, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):

	Year Ended December 31,
	2020			2019			2018
R&D revenue	$	5.0		$	0.1		$	6.6
Percentage of total revenue		1	%		0	%		1	%

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2020 and 2019, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):

	Year Ended December 31,
	2020			2019			2018
R&D revenue	$	1.0		$	187.4		$	50.6
Percentage of total revenue		0	%		17	%		8	%

Pfizer [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2020 and 2019, we earned the following revenue from our relationship with Pfizer (in millions, except percentage amounts):

	Year Ended December 31,
	2020			2019
R&D revenue	$	82.1		$	248.7
Percentage of total revenue		11	%		22	%

PTC Therapeutics [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2020, 2019 and 2018, we earned the following revenue from our relationship with PTC (in millions, except percentage amounts):

	Year Ended December 31,
	2020			2019			2018
Licensing and other royalty revenue (commercial revenue)	$	1.6		$	10.2		$	12.0
Percentage of total revenue		0	%		1	%		2	%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2020, 2019 and 2018, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):

	Year Ended December 31,
	2020			2019			2018
R&D revenue	$	5.9		$	57.0		$	8.3
Percentage of total revenue		1	%		5	%		1	%

Alnylam Pharmaceuticals, Inc. [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

In the fourth quarter 2020, we completed an arbitration process with Alnylam. The arbitration panel awarded us $41.2 million for payments owed to us by Alnylam related to Alnylam’s agreement with Sanofi Genzyme. We recognized the $41.2 million payment from Alnylam as revenue in the fourth quarter of 2020 because we did not have any performance obligations for the respective payment.

	Year Ended December 31,
	2020			2019			2018
R&D revenue	$	47.9		$	24.1		$	2.0
Percentage of total revenue		7	%		2	%		—